Skyrizi (risankizumab)

Product Name:

Skyrizi (risankizumab)

Categories: Dermatology, Immunology, Rheumatology

Discover Savings on Your Medication Access

Trusted concierge service, secure process, and real savings for patients in the U.S.

Table of Contents

Skyrizi (risankizumab-rzaa)

Product Category

Immunology / Dermatology / Gastroenterology

Brand Name

Skyrizi

Generic Name or Biosimilar

No generic or biosimilar available

Active Ingredient

Risankizumab-rzaa

Prescription Status

Prescription-only

Targeted Conditions

  • Moderate-to-severe plaque psoriasis in adults
  • Active psoriatic arthritis in adults
  • Moderate-to-severe Crohn’s disease in adults
  • Moderate-to-severe ulcerative colitis in adults

Off-Label Usage

  • Other autoimmune diseases under clinical research (e.g., hidradenitis suppurativa, lupus)

(Off-label usage should be restricted to clinical research or specialist guidance.)

Drug Classification Overview

Skyrizi is a humanized monoclonal antibody targeting interleukin-23 (IL-23).
It works by binding to the p19 subunit of IL-23, reducing inflammation associated with psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Manufacturer in the USA, Mexico, and Canada

USA: AbbVie Inc.
Mexico: AbbVie México, S.A. de C.V.
Canada: AbbVie Corporation

Available Strengths and Dosage Forms – United States, Mexico, and Canada

Country Comparison – United States vs Mexico and Canada

  • Equivalent formulation and dosing across all three countries
  • Packaging and injector devices may vary
  • Cold chain shipping required (injectable biologic)

Average Retail Price (Monthly Treatment)

Canada: Approximate savings of 35–55% vs U.S. retail
Mexico: Approximate savings of 30–50% vs U.S. retail

Savings vary depending on local regulations, pharmacy access, and cold chain requirements.

Where to Buy USA

  • Specialty pharmacies and hospital-based distribution centers (CVS Specialty, Walgreens Specialty, Optum, Accredo, etc.)

Access may require prior authorization and insurance approval.

Storage Requirements

  • Store refrigerated at 2°C to 8°C (36°F to 46°F)
  • Do not freeze; protect from light
  • May be kept at room temperature for up to 24 hours if needed

Key Benefits

  • Provides rapid and sustained skin clearance in psoriasis
  • Improves joint symptoms and physical function in psoriatic arthritis
  • Induces and maintains remission in Crohn’s disease and ulcerative colitis
  • Convenient dosing every 8 or 12 weeks (after initial loading)
  • Well-tolerated safety profile

Shipping from Canada

Skyrizi is accessed through licensed Canadian pharmacies regulated by Health Canada. MedicalMex coordinates access through certified specialty pharmacies and treatment centers.

MedicalMex facilitates:

  • Prescription verification and coordination
  • Cold chain–compliant shipping
  • Telehealth consultations with licensed specialists if needed
  • Insurance and payment support
  • Case management and bilingual patient support

Buying from Mexico

Skyrizi is available through certified pharmacies in Mexico regulated by COFEPRIS. MedicalMex facilitates patient access through licensed treatment centers.

MedicalMex facilitates:

  • Prescription handling with licensed physicians
  • Telehealth consultations if required
  • Travel coordination if in-person access is needed
  • Cold chain–compliant logistics
  • Concierge bilingual support

Side Effects

  • Common: Upper respiratory tract infections; Headache; Fatigue; Injection site reactions
  • Moderate: Fungal infections; Abdominal pain; Diarrhea
  • Serious: Hypersensitivity reactions; Increased risk of infections; Rare cases of malignancy

Patients should be monitored for infections and report serious or persistent symptoms immediately.

Warnings and Precautions

  • Do not use in patients with active infections
  • Screen for tuberculosis prior to initiation
  • Avoid live vaccines during treatment
  • Pregnancy and breastfeeding: safety not established

Alternative Medications (by Indication)

Other IL-23 inhibitors: Guselkumab (Tremfya), Tildrakizumab (Ilumya)
IL-12/23 inhibitor: Ustekinumab (Stelara)
Other biologics: Adalimumab (Humira), Secukinumab (Cosentyx), Ixekizumab (Taltz)
Traditional therapies: Methotrexate, Cyclosporine, Corticosteroids

Medication FAQs

Skyrizi is used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adults.

Skyrizi is given by subcutaneous injection or intravenous infusion depending on indication. Maintenance dosing is usually every 8–12 weeks.

Routine monitoring is not typically required, but patients should be screened for TB and monitored for infections.

No. It is a monoclonal antibody biologic that targets IL-23, not a corticosteroid.

Many patients see improvement within weeks, with sustained response over long-term use.

Yes. Skyrizi is a prescription-only medication that must be prescribed by a licensed specialist.

It may be combined with other medications under specialist supervision, but live vaccines should be avoided.

Yes. MedicalMex facilitates access through licensed pharmacies and treatment centers in both countries.

Yes. Cold chain handling is required during travel, using temperature-controlled storage.

Concierge services including prescription validation, Telehealth consultations, logistics, cold chain shipping, and bilingual support.